Valuation : Guided Therapeutics Inc

Market Cap 22.69M 19.59M 18.36M 16.76M 31.54M 2.16B 31.69M 218M 84.96M 1.09B 85.17M 83.32M 3.63B P/E 2024
-3x
P/E 2025 -12.7x
Enterprise Value 25.56M 22.07M 20.69M 18.89M 35.53M 2.44B 35.71M 245M 95.73M 1.23B 95.97M 93.88M 4.09B EV / Sales 2024
1,649x
EV / Sales 2025 64.4x
Free-Float
63.48%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 70 2023-03-05
Chief Tech/Sci/R&D Officer 70 2010-12-01
Director TitleAgeSince
Director/Board Member 70 2016-11-30
Director/Board Member 76 2006-04-09
Chairman 67 2013-09-30
Change 5-day change 1-year change 3-year change Capi.($)
+13.33%-.--% - - 22.69M
-1.35%-0.86%+27.46%+14.88% 233B
+0.18%+0.07%+5.40%-15.44% 152B
+1.51%-0.50%-20.92%+25.22% 130B
+0.36%-5.12%-55.76%-7.72% 67.64B
+0.29%+0.42%+11.51%+18.43% 51.85B
+0.66%-0.73%-16.25%-13.01% 50.91B
-2.44%-1.57%+29.61%+28.54% 44.46B
-1.56%+2.47%+40.75%+51.70% 41.39B
+1.94%+5.20%-14.76%+49.29% 34.01B
Average +1.27%-0.44%+0.78%+16.88% 89.42B
Weighted average by Cap. -0.18%-0.56%+3.74%+11.50%

Financials

2024 2025
Net sales 7K 6.04K 5.67K 5.17K 9.73K 668K 9.78K 67.16K 26.22K 338K 26.28K 25.71K 1.12M 767K 662K 621K 567K 1.07M 73.14M 1.07M 7.36M 2.87M 36.99M 2.88M 2.82M 123M
Net income -2.42M -2.09M -1.96M -1.79M -3.36M -230M -3.38M -23.19M -9.05M -117M -9.07M -8.88M -387M -3.2M -2.76M -2.59M -2.36M -4.44M -305M -4.46M -30.66M -11.97M -154M -12M -11.74M -511M
Net Debt 1.77M 1.53M 1.43M 1.31M 2.46M 169M 2.47M 16.99M 6.63M 85.42M 6.65M 6.5M 283M 2.88M 2.48M 2.33M 2.13M 4M 274M 4.02M 27.59M 10.77M 139M 10.8M 10.56M 460M
Logo Guided Therapeutics Inc
Guided Therapeutics, Inc. is a medical technology company. The Company is focused on developing medical devices that have the potential to improve healthcare. The Company’s primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care.
Employees
-